CN102145105A - 薯蓣科提取物及包含此提取物、用于预防或治疗外周神经疾病的组合物 - Google Patents
薯蓣科提取物及包含此提取物、用于预防或治疗外周神经疾病的组合物 Download PDFInfo
- Publication number
- CN102145105A CN102145105A CN2011100260217A CN201110026021A CN102145105A CN 102145105 A CN102145105 A CN 102145105A CN 2011100260217 A CN2011100260217 A CN 2011100260217A CN 201110026021 A CN201110026021 A CN 201110026021A CN 102145105 A CN102145105 A CN 102145105A
- Authority
- CN
- China
- Prior art keywords
- extract
- dioscorea
- extractant
- peripheral neuropathy
- rhizoma dioscoreae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000284 extract Substances 0.000 title claims abstract description 81
- 241000234272 Dioscoreaceae Species 0.000 title claims abstract description 36
- 239000000203 mixture Substances 0.000 title claims abstract description 31
- 208000033808 peripheral neuropathy Diseases 0.000 title claims abstract description 30
- 235000013305 food Nutrition 0.000 claims abstract description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 66
- 238000000034 method Methods 0.000 claims description 34
- 201000010099 disease Diseases 0.000 claims description 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- 238000000605 extraction Methods 0.000 claims description 17
- 244000281702 Dioscorea villosa Species 0.000 claims description 16
- 235000004879 dioscorea Nutrition 0.000 claims description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 15
- 241000908494 Dioscorea nipponica Species 0.000 claims description 12
- 235000017008 Dioscorea nipponica Nutrition 0.000 claims description 12
- 239000007864 aqueous solution Substances 0.000 claims description 10
- 235000005903 Dioscorea Nutrition 0.000 claims description 9
- 235000000504 Dioscorea villosa Nutrition 0.000 claims description 9
- 230000001476 alcoholic effect Effects 0.000 claims description 8
- 244000257739 Dioscorea bulbifera Species 0.000 claims description 6
- 235000008532 Dioscorea bulbifera Nutrition 0.000 claims description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- 229920006395 saturated elastomer Polymers 0.000 claims description 5
- 238000011287 therapeutic dose Methods 0.000 claims description 5
- 241000907616 Dioscorea tokoro Species 0.000 claims description 4
- 235000016420 Dioscorea tokoro Nutrition 0.000 claims description 4
- 235000002722 Dioscorea batatas Nutrition 0.000 claims description 3
- 240000008955 Dioscorea japonica Species 0.000 claims description 3
- 235000005251 Dioscorea japonica Nutrition 0.000 claims description 3
- 240000001811 Dioscorea oppositifolia Species 0.000 claims description 3
- 241000907618 Dioscorea tenuipes Species 0.000 claims description 3
- 235000016419 Dioscorea tenuipes Nutrition 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 abstract description 69
- 206010012601 diabetes mellitus Diseases 0.000 description 35
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 32
- 108010025020 Nerve Growth Factor Proteins 0.000 description 31
- 241000699670 Mus sp. Species 0.000 description 28
- 239000000243 solution Substances 0.000 description 27
- 102000015336 Nerve Growth Factor Human genes 0.000 description 25
- 229940053128 nerve growth factor Drugs 0.000 description 25
- 235000019441 ethanol Nutrition 0.000 description 23
- 239000000126 substance Substances 0.000 description 21
- 150000003839 salts Chemical class 0.000 description 17
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 16
- 239000000419 plant extract Substances 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 13
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 12
- 230000036541 health Effects 0.000 description 12
- 239000000600 sorbitol Substances 0.000 description 12
- 235000010356 sorbitol Nutrition 0.000 description 12
- 238000002347 injection Methods 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- 210000003497 sciatic nerve Anatomy 0.000 description 11
- 239000003814 drug Substances 0.000 description 10
- 239000012044 organic layer Substances 0.000 description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 206010029216 Nervousness Diseases 0.000 description 9
- 239000002775 capsule Substances 0.000 description 9
- 239000008103 glucose Substances 0.000 description 9
- 150000002632 lipids Chemical class 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 239000003826 tablet Substances 0.000 description 9
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 230000001537 neural effect Effects 0.000 description 8
- 230000002093 peripheral effect Effects 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 210000002569 neuron Anatomy 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 6
- 102000007072 Nerve Growth Factors Human genes 0.000 description 6
- 230000005540 biological transmission Effects 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000000287 crude extract Substances 0.000 description 6
- 230000034994 death Effects 0.000 description 6
- 210000005036 nerve Anatomy 0.000 description 6
- 239000003900 neurotrophic factor Substances 0.000 description 6
- 210000001428 peripheral nervous system Anatomy 0.000 description 6
- 238000001953 recrystallisation Methods 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 239000011230 binding agent Substances 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 239000007791 liquid phase Substances 0.000 description 5
- 230000014511 neuron projection development Effects 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 230000003442 weekly effect Effects 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 4
- 208000007241 Experimental Diabetes Mellitus Diseases 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- -1 chemical compound salt Chemical class 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 230000001771 impaired effect Effects 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 201000001119 neuropathy Diseases 0.000 description 4
- 230000007823 neuropathy Effects 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 229930002600 steroidal saponin Natural products 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 230000002421 anti-septic effect Effects 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- CHNUOJQWGUIOLD-NFZZJPOKSA-N epalrestat Chemical compound C=1C=CC=CC=1\C=C(/C)\C=C1/SC(=S)N(CC(O)=O)C1=O CHNUOJQWGUIOLD-NFZZJPOKSA-N 0.000 description 3
- 229950010170 epalrestat Drugs 0.000 description 3
- CHNUOJQWGUIOLD-UHFFFAOYSA-N epalrestate Natural products C=1C=CC=CC=1C=C(C)C=C1SC(=S)N(CC(O)=O)C1=O CHNUOJQWGUIOLD-UHFFFAOYSA-N 0.000 description 3
- 239000002778 food additive Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000003141 lower extremity Anatomy 0.000 description 3
- 239000012046 mixed solvent Substances 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 230000032696 parturition Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 210000000697 sensory organ Anatomy 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 230000005062 synaptic transmission Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- 208000007848 Alcoholism Diseases 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 208000000412 Avitaminosis Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 2
- 206010021135 Hypovitaminosis Diseases 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 208000002720 Malnutrition Diseases 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000028389 Nerve injury Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- 201000007930 alcohol dependence Diseases 0.000 description 2
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 2
- 239000003005 anticarcinogenic agent Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000000748 compression moulding Methods 0.000 description 2
- 208000018631 connective tissue disease Diseases 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- WQLVFSAGQJTQCK-UHFFFAOYSA-N diosgenin Natural products CC1C(C2(CCC3C4(C)CCC(O)CC4=CCC3C2C2)C)C2OC11CCC(C)CO1 WQLVFSAGQJTQCK-UHFFFAOYSA-N 0.000 description 2
- 208000016097 disease of metabolism Diseases 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 230000001071 malnutrition Effects 0.000 description 2
- 235000000824 malnutrition Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 230000008764 nerve damage Effects 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 210000002241 neurite Anatomy 0.000 description 2
- 230000000324 neuroprotective effect Effects 0.000 description 2
- 208000015380 nutritional deficiency disease Diseases 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000001294 propane Substances 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- NWMIYTWHUDFRPL-UHFFFAOYSA-N sapogenin Natural products COC(=O)C1(CO)C(O)CCC2(C)C1CCC3(C)C2CC=C4C5C(C)(O)C(C)CCC5(CCC34C)C(=O)O NWMIYTWHUDFRPL-UHFFFAOYSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 231100000167 toxic agent Toxicity 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 239000000814 tuberculostatic agent Substances 0.000 description 2
- 208000030401 vitamin deficiency disease Diseases 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 1
- 102000016912 Aldehyde Reductase Human genes 0.000 description 1
- 108010053754 Aldehyde reductase Proteins 0.000 description 1
- 229940118148 Aldose reductase inhibitor Drugs 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 1
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 1
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 1
- 0 CC[C@@]1[C@](C)CC[C@]2(C)[C@@](C*)[C@](CCCC(C)(CCC3)IC[C@@]3N=O)CC12 Chemical compound CC[C@@]1[C@](C)CC[C@]2(C)[C@@](C*)[C@](CCCC(C)(CCC3)IC[C@@]3N=O)CC12 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 102100029268 Neurotrophin-3 Human genes 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000003288 aldose reductase inhibitor Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000000823 artificial membrane Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- OAIVIYSBZFEOIU-UHFFFAOYSA-N chloroform;propan-2-one Chemical compound CC(C)=O.ClC(Cl)Cl OAIVIYSBZFEOIU-UHFFFAOYSA-N 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940074046 glyceryl laurate Drugs 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 230000030214 innervation Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229940041476 lactose 100 mg Drugs 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000002772 monosaccharides Chemical group 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 235000019462 natural additive Nutrition 0.000 description 1
- 230000001379 nervous effect Effects 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- 230000008288 physiological mechanism Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006223 plastic coating Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229950003937 tolonium Drugs 0.000 description 1
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 1
- 235000021404 traditional food Nutrition 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 239000002351 wastewater Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Botany (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Biomedical Technology (AREA)
- Polymers & Plastics (AREA)
- Neurosurgery (AREA)
- Nutrition Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
13C | 化学位移(δ)a | 1H | 化学位移(δ)a |
C-1 | 37.6-37.7 | H-1 | 1.60-1.70;0.87-0.91(m,o) |
C-2 | 30.3-30.4 | H-2 | 2.00-2.03;1.75-1.79(m,o) |
C-3 | 78.1-78.7 | H-3 | 3.81-3.90(m,J=4.7-5.6Hz) |
C-4 | 38.9-39.5 | H-4 | 2.57-2.29(m,J=13-14Hz;J=5.0;12.0Hz) |
C-5 | 140.9-141.1 | ||
C-6 | 121.9-122.0 | H-6 | 5.23-5.26(d,J=4.6-5.4Hz) |
C-7 | 32.4-32.5 | H-7 | 1.77-1.82;1.41-1.46(m,o) |
C-8 | 31.8-31.9 | H-8 | 1.44-1.48(m,o) |
C-9 | 50.4-50.5 | H-9 | 0.80-0.83(m) |
C-10 | 37.2-37.3 | ||
C-11 | ~21.3 | H-11 | 1.35-1.38(m,o) |
C-12 | 40.0-40.1 | H-12 | 1.60-1.62(m,o) |
C-13 | 40.6-40.7 | ||
C-14 | 56.8-56.8 | H-14 | 1.01(m,o) |
C-15 | 32.4-32.5 | H-15 | 1.95-1.98(m,J=5.9-6.1Hz);1.31-1.35(m,o) |
C-16 | 81.3-81.3 | H-16 | 4.45-4.48(m,J=7.0-7.4Hz) |
C-17 | 63.0-63.1 | H-17 | 1.72-1.75(m,o) |
C-18 | 16.5-16.6 | H-18 | 0.73-0.76(s) |
C-19 | 19.6-19.6 | H-19 | 0.80-1.00(s) |
C-20 | 42.1-42.2 | H-20 | 1.88(m) |
C-21 | 15.2-15.2 | H-21 | 1.05-1.07(d,J=6.8-7.2Hz) |
C-22 | 109.4-109.5 | ||
C-23 | 32.0-32.0 | H-23 | 1.57-1.63(m,o) |
C-24 | 29.4-29.5 | H-24 | 1.48-1.52(m,o) |
C-25 | 30.8-30.8 | H-25 | 1.50(m,o) |
C-26 | 67.0-67.1 | H-26 | 3.50-3.40(m,J=10.5;3.0;10.5Hz) |
C-27 | 17.5-17.5 | H-27 | 0.60-0.63(d,J=4.7-5.8Hz) |
Claims (10)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2005-0102450 | 2005-10-28 | ||
KR20050102450 | 2005-10-28 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2006800401941A Division CN101296703B (zh) | 2005-10-28 | 2006-10-27 | 薯蓣科提取物及包含此提取物、用于预防或治疗外周神经疾病的组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102145105A true CN102145105A (zh) | 2011-08-10 |
CN102145105B CN102145105B (zh) | 2013-07-03 |
Family
ID=37968005
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2011100260217A Active CN102145105B (zh) | 2005-10-28 | 2006-10-27 | 薯蓣科提取物及包含此提取物、用于预防或治疗外周神经疾病的组合物 |
CN2006800401941A Active CN101296703B (zh) | 2005-10-28 | 2006-10-27 | 薯蓣科提取物及包含此提取物、用于预防或治疗外周神经疾病的组合物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2006800401941A Active CN101296703B (zh) | 2005-10-28 | 2006-10-27 | 薯蓣科提取物及包含此提取物、用于预防或治疗外周神经疾病的组合物 |
Country Status (14)
Country | Link |
---|---|
US (2) | US20090041865A1 (zh) |
EP (1) | EP1942920B1 (zh) |
JP (1) | JP5166272B2 (zh) |
KR (1) | KR100854621B1 (zh) |
CN (2) | CN102145105B (zh) |
BR (1) | BRPI0617443A2 (zh) |
CA (1) | CA2623838A1 (zh) |
ES (1) | ES2634227T3 (zh) |
HU (1) | HUE035328T2 (zh) |
PL (1) | PL1942920T3 (zh) |
PT (1) | PT1942920T (zh) |
RU (2) | RU2430737C2 (zh) |
TR (1) | TR201708352T4 (zh) |
WO (1) | WO2007049932A1 (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100811683B1 (ko) * | 2006-11-21 | 2008-03-11 | 영남대학교 산학협력단 | 마 추출물을 유효성분으로 포함하는 장 기능 개선용 조성물및 이를 함유하는 기능성 건강식품 |
KR101341692B1 (ko) | 2011-03-16 | 2013-12-20 | 동아에스티 주식회사 | 복합생약추출물을 함유하는 당뇨병성 말초 신경병증의 치료 및 예방을 위한 조성물 |
KR101341693B1 (ko) * | 2011-03-16 | 2013-12-16 | 동아에스티 주식회사 | 생약추출물을 함유하는 퇴행성 신경질환의 치료 및 예방을 위한 조성물 |
CN104119420A (zh) * | 2013-04-25 | 2014-10-29 | 四川大学华西医院 | 薯蓣皂苷糖基化衍生物及其制备方法和用途 |
KR101689514B1 (ko) * | 2015-03-27 | 2016-12-27 | 한국 한의학 연구원 | 천산룡 약재의 감별방법 |
KR101695207B1 (ko) * | 2015-07-31 | 2017-01-11 | 한국 한의학 연구원 | 상륙 추출물을 유효성분으로 함유하는 항암제 유발 말초신경병증 예방 또는 치료용 약학적 조성물 |
KR101732483B1 (ko) | 2016-07-06 | 2017-05-24 | 한국 한의학 연구원 | 연교 추출물을 유효성분으로 함유하는 말초신경병증 예방, 개선 또는 치료용 조성물 |
KR102298839B1 (ko) * | 2019-01-04 | 2021-09-07 | 주식회사 디네이쳐 | 천연물질의 선택적 추출 방법 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101244066A (zh) * | 2007-02-14 | 2008-08-20 | 成都地奥制药集团有限公司 | 甾体总皂苷提取物的新用途 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61106516A (ja) * | 1984-10-29 | 1986-05-24 | Osaka Chem Lab | 血糖降下剤 |
JP2911057B2 (ja) * | 1991-01-18 | 1999-06-23 | 高砂香料工業株式会社 | 感染防御剤及び感染防御効果を有する機能性食品 |
US5252729A (en) * | 1991-10-23 | 1993-10-12 | Schering Corporation | Extraction of compounds from plant materials using supercritical fluids |
JP4313435B2 (ja) * | 1995-07-24 | 2009-08-12 | トラスティーズ オブ ボストン ユニバーシティー | プレグネノロンサルフェート誘導体によるnmdaレセプター活性の抑制 |
KR19990000201A (ko) * | 1997-06-03 | 1999-01-15 | 유현식 | 농업용 필름의 안개방지성능 평가장치 |
CN1131237C (zh) * | 1997-09-26 | 2003-12-17 | 中国人民解放军军事医学科学院放射医学研究所 | 甾体皂甙防治老年性痴呆的用途及新的甾体皂甙 |
KR20000008809A (ko) * | 1998-07-16 | 2000-02-15 | 피영준 | 한방녹심원의 제조방법 |
KR20030020585A (ko) * | 2001-09-03 | 2003-03-10 | 박재형 | 중추신경세포의 뉴로제네시스를 촉진하고 아폽토시스를억제하는 생약 조성물 |
NZ547344A (en) | 2002-03-27 | 2007-11-30 | Phytopharm Plc | Therapeutic methods and uses of sapogenins and their derivatives |
KR100543342B1 (ko) * | 2002-06-28 | 2006-01-20 | 한국 한의학 연구원 | 뇌신경세포의 손상을 치료하기 위한 한약재 조성물 |
CN1228344C (zh) * | 2002-10-21 | 2005-11-23 | 吉林天药科技股份有限公司 | 薯蓣皂苷的制备方法、药物制剂及其医药新用途 |
CN1416816A (zh) * | 2002-11-08 | 2003-05-14 | 吉林天药科技股份有限公司 | 薯蓣皂苷的抗肿瘤作用及其药物制剂 |
US20040126447A1 (en) * | 2002-12-31 | 2004-07-01 | Rong-Tsun Wu | Extract of Dioscorea sp. and the medical uses thereof |
CN1202830C (zh) * | 2002-12-31 | 2005-05-25 | 中日友好临床医学研究所 | 穿山龙及其薯蓣总皂苷在治疗慢性肾小球肾炎中的新用途 |
US20050019435A1 (en) * | 2003-07-21 | 2005-01-27 | Jeffrey Young | Method of treating non-insulin dependent diabetes mellitus and related complications |
CN1560061A (zh) * | 2004-03-10 | 2005-01-05 | 上海大学 | 怀山药提取物怀山药皂甙的提取方法 |
KR100842052B1 (ko) * | 2004-05-19 | 2008-06-30 | 한국 한의학 연구원 | 뇌혈관 질환 예방 및 치료용 조성물 |
-
2006
- 2006-10-27 US US12/084,149 patent/US20090041865A1/en not_active Abandoned
- 2006-10-27 PL PL06812249T patent/PL1942920T3/pl unknown
- 2006-10-27 TR TR2017/08352T patent/TR201708352T4/tr unknown
- 2006-10-27 EP EP06812249.8A patent/EP1942920B1/en active Active
- 2006-10-27 HU HUE06812249A patent/HUE035328T2/en unknown
- 2006-10-27 CA CA002623838A patent/CA2623838A1/en not_active Abandoned
- 2006-10-27 KR KR1020060104935A patent/KR100854621B1/ko active IP Right Grant
- 2006-10-27 BR BRPI0617443-4A patent/BRPI0617443A2/pt not_active Application Discontinuation
- 2006-10-27 CN CN2011100260217A patent/CN102145105B/zh active Active
- 2006-10-27 WO PCT/KR2006/004408 patent/WO2007049932A1/en active Application Filing
- 2006-10-27 RU RU2008115631/15A patent/RU2430737C2/ru active
- 2006-10-27 CN CN2006800401941A patent/CN101296703B/zh active Active
- 2006-10-27 RU RU2011102693/15A patent/RU2453327C1/ru active
- 2006-10-27 PT PT68122498T patent/PT1942920T/pt unknown
- 2006-10-27 JP JP2008537601A patent/JP5166272B2/ja active Active
- 2006-10-27 ES ES06812249.8T patent/ES2634227T3/es active Active
-
2010
- 2010-02-24 US US12/659,051 patent/US8202554B2/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101244066A (zh) * | 2007-02-14 | 2008-08-20 | 成都地奥制药集团有限公司 | 甾体总皂苷提取物的新用途 |
Also Published As
Publication number | Publication date |
---|---|
HUE035328T2 (en) | 2018-05-02 |
CA2623838A1 (en) | 2007-05-03 |
EP1942920B1 (en) | 2017-04-26 |
US20100159043A1 (en) | 2010-06-24 |
JP5166272B2 (ja) | 2013-03-21 |
ES2634227T3 (es) | 2017-09-27 |
US20090041865A1 (en) | 2009-02-12 |
CN101296703A (zh) | 2008-10-29 |
RU2008115631A (ru) | 2009-12-10 |
PL1942920T3 (pl) | 2017-11-30 |
EP1942920A1 (en) | 2008-07-16 |
CN101296703B (zh) | 2011-07-27 |
US8202554B2 (en) | 2012-06-19 |
WO2007049932A1 (en) | 2007-05-03 |
RU2453327C1 (ru) | 2012-06-20 |
JP2009513626A (ja) | 2009-04-02 |
CN102145105B (zh) | 2013-07-03 |
PT1942920T (pt) | 2017-07-25 |
KR20070045988A (ko) | 2007-05-02 |
RU2430737C2 (ru) | 2011-10-10 |
EP1942920A4 (en) | 2011-10-19 |
BRPI0617443A2 (pt) | 2011-07-26 |
TR201708352T4 (tr) | 2018-11-21 |
KR100854621B1 (ko) | 2008-08-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102145105B (zh) | 薯蓣科提取物及包含此提取物、用于预防或治疗外周神经疾病的组合物 | |
CN101035548B (zh) | 甾体皂苷药物组合物及其制备方法和应用 | |
KR20190010506A (ko) | 저분자 유효 사포닌의 함량이 증대되고 벤조피렌은 저감된 돌외잎 추출물의 제조방법 및 이에 따른 돌외잎 추출물 | |
CN103608025B (zh) | 用于预防或治疗神经退行性疾病的包含草药提取物的组合物 | |
CN101953864B (zh) | 青阳参甙(苷)元和包含它的提取物的医药用途 | |
CN105050608A (zh) | 含有硫化和非硫化聚阴离子多糖的藻类提取物及其应用 | |
WO2015190872A1 (ko) | 스피루리나 추출물을 유효성분으로 함유하는 비만 예방 및 치료용 약학적 조성물 | |
DE60216118T2 (de) | Sesquiterpenoid-derivate mit adipozytendifferenzierungshemmender wirkung | |
AU2003218547B2 (en) | A method of treating diabetes mellitus including conditions associated with diabetes mellitus and complications of diabetes mellitus | |
CN106822095A (zh) | 一种防治脂肪肝和肥胖的药物及其在制药中的应用 | |
JP2002255804A (ja) | インシュリン様作用を有するヘキサオキシジフェン酸誘導体を含んでなる組成物 | |
CN102028198A (zh) | 一种用于增强免疫力的组合物及其制备方法 | |
CN104127816A (zh) | 一种治疗糖尿病的药物组合物及其制备方法和用途 | |
CN104605344A (zh) | 一种增强免疫力的保健食品及其制备方法 | |
CN115886258B (zh) | 一种改善生理性记忆力衰减的复合益生菌组合物 | |
KR101281226B1 (ko) | 마이크로 전분입자로 코팅한 발효성 유산균을 함유한 홍삼 | |
KR20190093849A (ko) | 김네마 실베스트레 추출물 또는 이로부터 분리한 화합물을 유효성분으로 포함하는 당뇨병 예방 또는 치료용 조성물 | |
KR20230099461A (ko) | 누에 분말 추출물을 포함하는 이상지질혈증 예방, 개선 또는 치료용 조성물 | |
CN118267412A (zh) | 木姜叶柯提取物、制备方法和在降血糖方面的应用 | |
KR101065610B1 (ko) | 둥근마 조추출물 또는 분획물을 유효성분으로 함유하는비만증의 예방 및 치료용 조성물 | |
KR20160053091A (ko) | 택사 추출물, 이의 분획물 또는 이로부터 분리된 화합물을 포함하는 골질환의 예방 또는 치료용 약학적 조성물 | |
CN100486612C (zh) | 柴芩软胶囊及其制备和用途 | |
CN114224928A (zh) | 地胆头提取物在调节神经递质、改善焦虑行为方面的应用 | |
KR20070070311A (ko) | 다슬기, 유황오리, 유근피, 송화가루, 산청목, 죽염,인진쑥, 도라지 및 흑두로 구성되는 복합제 추출물을포함하는 비만 및 고콜레스테롤증 예방 및 치료를 위한조성물 | |
CN115192602A (zh) | 一种复合益生元及其在调节肠道功能中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160120 Address after: Seoul, South Kerean Patentee after: Industry Academic Cooperation Address before: Seoul, South Kerean Patentee before: Jin Shanli Patentee before: Jiang Donghao Patentee before: Pu Zhihao |
|
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20110810 Assignee: KK DONG-A ST Assignor: Industry Academic Cooperation Contract record no.: 2017990000035 Denomination of invention: Extract of the family dioscoreaceae and composition for preventing or treating peripheral neuropathy comprising the same Granted publication date: 20130703 License type: Exclusive License Record date: 20170125 |